Company: MDCXW
Filing Date: 2025-06-13
Form Type: PRE 14A
Source: 0001062993-25-011673
Chunk: 37

Company: Medicus Pharma Ltd.
Filing Date: 2025-06-13
Form: PRE 14A
Chunk 37
---
 or she is hereby authorized and directed, for and on behalf of the Company, to execute and deliver all such documents and to do all such other acts or things as he or she may determine to be necessary or advisable to give effect to this resolution, the execution of any such document or the doing of any such other act or thing being conclusive evidence of such determination."

In order to pass the By-Law Resolution, at least a majority of the votes cast by the Shareholders present at the Meeting in person or by proxy must be voted in favor of the By-Law Resolution. If the By-Law Resolution does not receive the requisite shareholder approval, the previous By-Law No. 1, which provided for a 10% quorum requirement at meetings of Shareholders, will be reinstated.

THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE "" THE QUORUM AMENDMENT IN PROPOSAL 3.

<div align='center'>- 29 -

PROPOSAL 4 - ISSUANCE OF SHARES UNDER NASDAQ 20% RULE</div>

Under Nasdaq Rule 5635(d) (the "Nasdaq 20% Rule"), a Nasdaq-listed company must obtain shareholder approval prior to issuing (or potentially issuing) common share (or securities convertible into or exercisable for common share) in a transaction, other than a public offering as defined under Nasdaq Rules, if the issuance equals 20% or more of the company's outstanding common shares (or 20% or more of the voting power), at a per-share price below the "Minimum Price" (as defined under Nasdaq Rule 5635(d)) at the time of issuance.

Standby Equity Purchase Agreement

On February 10, 2025, the Company entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN, Ltd. ("Yorkville"). Pursuant to the SEPA and subject to the satisfaction of certain conditions, Yorkville has committed to purchase the Common Shares from the Company in increments (each purchase, an "Advance") with an aggregate gross sales price of up to $15,000,000 during the 36 months following the date of the SEPA (such shares, the "SEPA Shares"). The SEPA Shares will be sold at the Company's option pursuant to the SEPA at 97% of then-applicable market price (as determined in accordance with the SEPA), subject to the Company's right to set a minimum acceptable price in